Cancer Genetics

You have full text access to this OnlineOpen article

Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors

  1. Maria Aparecida Nagai1,†,*,
  2. Nancy da Rós1,
  3. Mário Mourão Neto2,
  4. Silvio Rodrigues de Faria Junior3,
  5. Maria Mitzi Brentani1,
  6. Roberto Hirata Jr.4,
  7. Eduardo Jordão Neves3

Article first published online: 20 MAY 2004

DOI: 10.1002/ijc.20329

Issue

International Journal of Cancer

International Journal of Cancer

Volume 111, Issue 6, pages 892–899, 10 October 2004

Additional Information

How to Cite

Nagai, M. A., da Rós, N., Neto, M. M., de Faria Junior, S. R., Brentani, M. M., Hirata, R. and Neves, E. J. (2004), Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors. Int. J. Cancer, 111: 892–899. doi: 10.1002/ijc.20329

Author Information

  1. 1

    Disciplina de Oncologia, Departamento de Radiologia da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

  2. 2

    Departmento de Mastologia, Hospital do Câncer A.C. Camargo, São Paulo, Brazil

  3. 3

    Instituto de Matemática e Estatística da Universidade de São Paulo, São Paulo, Brazil

  4. 4

    SENAC College of Computer Science and Technology, São Paulo, Brazil

  1. †

    Fax: +55-11-3069-7292

*Disciplina de Oncologia, Departamento de Radiologia da Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Arnaldo, 455, 4° Andar, CEP-01296-903, São Paulo, Brazil

Publication History

  1. Issue published online: 3 AUG 2004
  2. Article first published online: 20 MAY 2004
  3. Manuscript Accepted: 26 FEB 2004
  4. Manuscript Revised: 20 JAN 2004
  5. Manuscript Received: 6 OCT 2003

Funded by

  • Fundaćao Amparo à Pesquisado Estadode São Paulo (FAPESP). Grant Number: 99/07009-4

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (152K)

REFERENCES

  • 1
    Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J Mamm Gland Biol Neoplasia 1998; 3: 49–61.
  • 2
    Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA. Mechanisms of estrogen action. Physiol Rev 2001; 81: 1535–65.
  • 3
    Hall MJ, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001; 276: 36869–72.
  • 4
    Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000; 74: 311.
  • 5
    Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA, Safe S. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (SP1) promoter elements. J Biol Chem 2000; 275: 5379–87.
  • 6
    Sabbah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a camp response-like element. Proc Natl Acad Sci USA 1999; 96: 11217–22.
  • 7
    Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, Kushner PJ. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 1999; 13: 1672–85.
  • 8
    Castro-Rivera E, Samudio I, Safe S. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 2001; 276: 30853–61.
  • 9
    Khan S, Abdelrahim M, Samudio I, Safe S. Estrogen receptor/SP1 complexes are required for induction of cad gene expression by 17beta-estradiol in breast cancer cells. Endocrinology 2003; 144: 2325–35.
  • 10
    Kato S, Kitamoto T, Masuhiro Y, Yanagisawa J. Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Oncology 1998; 55: 5–10.
  • 11
    Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol 2001; 11: 339–52.
  • 12
    Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK, Osborne CK, Dowsett M. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res 2000; 6: 616–21.
  • 13
    Yang J, Guzman R, Nandi S. Reconstituted normal human breast in nude mice: estrogen and progesterone receptors regulation. In Vivo 200; 15: 239–44.
  • 14
    Nagai MA, Marques LA, Yamamoto L, Fujiyama CT, Brentani MM. Estrogen and progesterone receptor mRNA levels in primary breast cancer: association with patient survival and other clinical and tumor features. Int J Cancer 1994; 59: 351–6.
    Direct Link:
  • 15
    Lemieux P, Fuqua S. The role of the estrogen receptor in tumor progression. J Steroid Biochem Mol Biol 1996; 56: 87–91.
  • 16
    Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998; 51: 227–38.
  • 17
    Hahnel R, Woodings T, Vivian AB. Prognostic value of estrogen receptors in primary breast cancer. Cancer 1979; 44: 671–5.
    Direct Link:
  • 18
    Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46( Suppl 12): 2884–8.
    Direct Link:
  • 19
    Robertson JF. Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 1996; 73: 5–12.
  • 20
    Sheikh MS, Garcia M, Pujol P, Fontana, JA, Rochefort H. Why are estrogen receptor-negative breast cancers more agressive than the estrogen receptor-positive breast cancers? Inv Metastasis 1994; 14: 329–36.
  • 21
    Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE, Venter DJ. Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res 2002; 62: 1289–95.
  • 22
    Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO, Botstein D. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999; 96: 9212–7.
  • 23
    Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747–52.
  • 24
    Bertucci F, Hougatte R., Benziane A, Gran JE, Adelaide J, Tagett R, Loriod B, Jacquemier J, Viens P, Jordan B, Birnbaum D, Nguyn C. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 2000;: 2981–91.
  • 25
    Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, Kaufmann M. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002; 359: 131–2.
  • 26
    Van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530–6.
  • 27
    Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869–74.
  • 28
    Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS, Chin KV. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 2000; 60: 4161–6.
  • 29
    Lonning PE, Sorlie T, Perou CM, Brown PO, Botstein D, Borresen-Dale AL. Microarrays in primary breast cancer-lessons from chemotherapy studies. Endocr Relat Cancer 2001; 8: 259–63.
  • 30
    Brentani MM, Nagai MA, Fujyama CT, Góes JCS. Steroid receptors in a group of brazilian breast cancer patients. J Surg Oncol 1981; 18: 431–9.
    Direct Link:
  • 31
    Chomczynski P, Sacchi N. Single-step method of rna isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156–9.
  • 32
    Dias Neto E, Correa RG, Verjovski-Almeida S, Briones MR, Nagai MA, da Silva W Jr, Zago MA, Bordin S, Costa FF, Goldman GH, Carvalho AF, Matsukuma A, et al. Shotgun sequencing of the human transcriptome with ORF expressed sequence tags. Proc Natl Acad Sci USA 2000; 97: 3491–6.
  • 33
    Edwards D. Non-linear normalization and background correction in one-channel cDNA microarray studies. Bioinformatics 2003; 19: 825–33.
  • 34
    Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucl Acids Res 2002; 30: E15.
  • 35
    Hastie T, Tibshirani R, Friedman J. The elements of statistical learning. New York: Springer, 2001.
  • 36
    Heinemeyer T, Chen X, Karas H, Kel AE, Kel OV, Liebich I, Meinhardt T, Reuter I, Schacherer F, Wingender E. Expanding the transfac database towards an expert system of regulatory molecular mechanisms. Nucl Acids Res 1999; 27: 318–22.
  • 37
    Nomura N, Miyajima N, Sazuka T, Tanaka A, Kawarabayasi Y, Sato S, Nagase T, Seki N, Ishikawa K, Tabata S. Prediction of the coding sequences of unidentified human genes: 1, the coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line kg-1. DNA Res 1994; 1: 27–35.
  • 38
    Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, Levkau B, Nitsch RM. The human diminuto/DWARF1 homolog Seladin-1 confers resistance to alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci 2000; 20: 7345–52.
  • 39
    Waterham HR, Koster J, Romeijn GJ, Hennekam RC, Vreken P, Andersson HC, Fitzpatrick DR, Kelley RI, Wanders RJ. Mutations in the 3beta-hydroxysterol delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 2001; 69: 685–94.
  • 40
    Nagai MA, Ros N, Bessa SA, Neto MM, Miracca, EC, Brentani MM. Differentially expressed genes and estrogen receptor status in breast cancer. Int J Oncol 2003; 23: 1425–30.
  • 41
    Li X, Greenwald I. Additional evidence for an eight-transmembrane-domain topology for caenorhabditis elegans and human presenilins. Proc Natl Acad Sci USA 1998; 95: 7109–14.
  • 42
    Cruts M, van Duijn CM, Backhovens H, van den Broeck M, Wehnert A, Serneels S, Sherrington R, Hutton M, Hardy J, St George-Hyslop PH, Hofman A, van Broeckhoven C. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile alzheimer disease. Hum Mol Genet 1998; 7: 43–51.
  • 43
    Inestrosa NC, Marzolo MP, Bonnefont AB. Cellular and molecular basis of estrogen's neuroprotection: potential relevance for Alzheimer's disease. Mol Neurobiol 1998; 17: 73–86.
  • 44
    Green PS, Gridley KE, Simpkins JW. Estradiol protects against beta-amyloid (25-35)-induced toxicity in sk-n-sh human neuroblastoma cells. Neurosci Lett 1996; 218: 165–8.
  • 45
    Manthey D, Heck S, Engert S, Behl C. Estrogen induces a rapid secretion of amyloid beta precursor protein via the mitogen-activated protein kinase pathway. Eur J Biochem 2001; 268: 4285–91.
    Direct Link:
  • 46
    Welsch PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, Warrington JA, King MC. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA 2002; 99: 7560–5.
  • 47
    Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM. Role of direct interaction in brca1 inhibition of estrogen receptor activity. Oncogene 2001; 20: 77–87.
  • 48
    Cyr DM, Langer T, Douglas MG. Dnaj-like proteins: molecular chaperones and specific regulators of hsp70. Trends Biochem Sci 1994; 19: 176–81.
  • 49
    Caplan AJ, Cyr DM, Douglas MG. Eukaryotic homologues of escherichia coli dnaj: a diverse protein family that functions with hsp70 stress proteins. Mol Biol Cell 1993; 4: 555–63.
  • 50
    Schneider T, Soti C, Cheetham ME, Miyata Y, Yahara I, Csermely P. Interaction of the human dnaj homologue, hsj1b with the 90 kda heat shock protein, hsp90. Life Sci 2000; 67: 1455–65.
  • 51
    Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63: 451–86.
  • 52
    Johnson JL, Craig EA. A role for the hsp40 ydj1 in repression of basal steroid receptor activity in yeast. Mol Cell Biol 2000; 20: 3027–36.
  • 53
    Swanson MS, Dreyfuss G. Classification and purification of proteins of heterogeneous nuclear ribonucleoprotein particles by rna-binding specificities. Mol Cell Biol 1988; 8: 2237–41.
  • 54
    Desjardins E, Hay N. Repeated CT elements bound by zinc finger proteins control the absolute and relative activities of the two principal human c-myc promoters. Mol Cell Biol 1993; 13: 5710–24.
  • 55
    Ritchie SA, Pasha MK, Batten DJ, Sharma RK, Olson DJ, Ross AR, Bonham K. Identification of the SRC pyrimidine-binding protein (SPY) as hnrnp k: implications in the regulation of SRC1a transcription. Nucl Acids Res 2003; 31: 1502–13.
  • 56
    Mandal M, Vadlamudi R, Nguyen D, Wang RA, Costa L, Bagheri-Yarmand R, Mendelsohn J, Kumar R. Growth factors regulate heterogeneous nuclear ribonucleoprotein k expression and function. J Biol Chem 2001; 276: 9699–704.
View Full Article (HTML) Get PDF (152K)